[Expert consensus on the diagnosis and treatment of excessive daytime sleepiness in obstructive sleep apnea].

Regular monitoring of the efficacy and safety of wake-promoting agents is recommended. The frequency of monitoring should be determined clinically, using subjective EDS scales, and supplemented by objective assessments when available. Strict monitoring for adverse effects is required during treatment, including the risk of drug dependence, addiction, and cardiovascular events. Caution should be exercised when prescribing these agents to patients with cardiovascular risk factors (3, B).